Wire · operational-macro
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 November 2026 · Fusion42 review
The FDA granted Fast Track designation to FRP-003, an oral botanical drug candidate by Front Range Pharmaceuticals, for treating Long COVID fatigue, enabling closer regulatory interaction ahead of a phase 2 trial enrolling 220 adults. The trial will measure fatigue reduction and secondary outcomes including sleep, anxiety, cognition, and inflammatory biomarkers, addressing a significant unmet need with no approved treatments.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to accelerate your clinical planning if you're developing Long COVID treatments because the FDA is signalling faster routes to market for promising therapies. The pressure on no-approved-treatment categories means regulatory gatekeepers are opening doors now that were closed before.
◆ Coverage
1 source · 12 Nov 2026
◆ Related on Wire
◆ Topics